Drug Profile
Brontictuzumab
Alternative Names: Anti-Notch 1; Anti-Notch 1 monoclonal antibody; OMP-52M51Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator OncoMed Pharmaceuticals
- Developer OncoMed Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Notch-1 receptor antagonists; Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Adenoid cystic carcinoma; Colorectal cancer; Solid tumours
- Discontinued Haematological malignancies
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 24 Apr 2019 OncoMed Pharmaceuticals has been acquired by Mereo BioPharma
- 28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Adenoid-cystic-carcinoma in USA (IV)